This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Emcure Q2 FY27 consolidated: revenue up 24.3%, PAT up 29.3%
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Smallcap 250 and 3.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 ended September 30, 2026: revenue rose 24.3% year on year to INR 28,205 million from INR 22,698 million, PAT rose 29.3% to INR 3,251 million from INR 2,514 million, and EBITDA margin widened 103 basis points to 20.4%. Half-year consolidated revenue was INR 54,009 million, up 23.6%, PAT up 32.5% to INR 6,176 million. Standalone quarter PAT was INR 2,484 million, up 111%.
Positive for the stock: revenue, profit and margins rose, with an unmodified auditor review. Watch currency swings and integration risk.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹2,820 Cr | ₹2,270 Cr | +24.3% |
| Operating profit | ₹442.6 Cr | ₹338.3 Cr | +30.8% |
| Profit after tax | ₹325.1 Cr | ₹251.4 Cr | +29.3% |
| EBITDA margin | 20.8% | 20.9% | −0.1 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.